VanEck Biotech ETF (NASDAQ:BBH) Short Interest Down 69.4% in March

VanEck Biotech ETF (NASDAQ:BBH) was the target of a large drop in short interest during the month of March. As of March 13th, there was short interest totaling 5,065 shares, a drop of 69.4% from the February 26th total of 16,556 shares. Based on an average daily trading volume, of 6,457 shares, the days-to-cover ratio is presently 0.8 days. Approximately 0.3% of the shares of the company are sold short.

Hedge Funds Weigh In On VanEck Biotech ETF

A number of institutional investors have recently made changes to their positions in the business. Corient Private Wealth LLC lifted its holdings in shares of VanEck Biotech ETF by 9.6% during the fourth quarter. Corient Private Wealth LLC now owns 5,483 shares of the company’s stock worth $1,041,000 after buying an additional 478 shares during the last quarter. Empowered Funds LLC acquired a new position in shares of VanEck Biotech ETF in the 4th quarter valued at $38,000. MML Investors Services LLC bought a new position in shares of VanEck Biotech ETF during the 4th quarter worth about $384,000. Evelyn Partners Asset Management Ltd boosted its position in shares of VanEck Biotech ETF by 16.9% during the 4th quarter. Evelyn Partners Asset Management Ltd now owns 941 shares of the company’s stock valued at $178,000 after acquiring an additional 136 shares in the last quarter. Finally, Atlas Capital Advisors Inc. bought a new stake in VanEck Biotech ETF in the fourth quarter valued at about $1,079,000. 32.05% of the stock is currently owned by institutional investors.

VanEck Biotech ETF Trading Up 1.7%

Shares of BBH opened at $185.37 on Thursday. VanEck Biotech ETF has a one year low of $135.34 and a one year high of $202.91. The company’s fifty day moving average price is $193.31 and its 200 day moving average price is $186.32.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.